Biolase, Inc.
BIOL
BIOL was delisted on the 18th of June, 2024.
30 hedge funds and large institutions have $38.5M invested in Biolase, Inc. in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 4 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
4% less capital invested
Capital invested by funds: $40.1M → $38.5M (-$1.65M)
12% less funds holding
Funds holding: 34 → 30 (-4)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.18M |
| 2 |
TMC
Trellus Management Company
Delray Beach,
Florida
|
+$308K |
| 3 |
GIP
Granite Investment Partners
El Segundo,
California
|
+$109K |
| 4 |
Millennium Management
New York
|
+$72.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$18.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$272K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$218K |
| 3 |
Renaissance Technologies
New York
|
-$83K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$62K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$54.4K |
BIOL Hedge Fund Activity: Q1 2017 in Review
30 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q1 2017, worth a combined $38.5M — down 4.1% from $40.1M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BIOL and 3 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 5 added.
The largest buyer was BlackRock, opening a new position worth an estimated $2.18M. The largest seller was Consonance Capital Management, cutting an estimated $272K.
- 30 institutional investors held Biolase, Inc. (BIOL) as of Q1 2017, down from 34 in Q4 2016.
- Funds reported $38.5M of Biolase, Inc. stock for Q1 2017, down 4.1% quarter-over-quarter.
- 3 funds opened new Biolase, Inc. positions in Q1 2017 and 4 closed out, a net change of -1 holder.
- The largest Biolase, Inc. buyer in Q1 2017 was BlackRock, an estimated $2.18M added.
- The largest Biolase, Inc. seller in Q1 2017 was Consonance Capital Management, an estimated $272K sold.
Based on aggregated 13F filings for Q1 2017.